Case Report

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy

Li-Jun Xue, Xiao-Bei Mao, Xiao-Bei Liu, Quan-Sheng Su, Hong-Ju Yu, and Ji-Hong Yang

Department of Oncology and Hematology, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhong-shan Road, Nanjing, Jiangsu Province 210002, China

Correspondence should be addressed to Ji-Hong Yang, yangjihong2@medmail.com.cn

Received 28 August 2010; Revised 21 November 2010; Accepted 12 December 2010

Academic Editor: Yolanda T. Becker

Copyright © 2010 Li-Jun Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peripheral T-cell lymphoma (PTCL) is rare and difficult to treat for its high relapse rate. The authors report a case of PTCL of the skin, regarding which clinical and pathological features, treatment, and prognosis were discussed. A 66-year-old woman was admitted with complaints of enlarging erythematous noduloplaques on the right anterior tibial skin for one year and similar lesions on the left for 6 months. Surgical resection of right leg lesion and biopsy of enlarged inguinal lymph nodes histologically indicated a PTCL of the nasal type. The patient was treated by CHOP plus bortezomib, reached complete remission just after two courses of chemotherapy and then received another two as consolidation. The patient remained in remission for 11 months until local relapse. As for cutaneous lesions, detailed lymph node examination and prompt tissue biopsy are judicious choices prior to any medical management. The chemotherapy consisting of bortezomib and CHOP is safe and efficient in PTCL of the skin.

1. Introduction

Peripheral T-cell lymphoma (PTCL), accounting for less than 15% of non-Hodgkin’s lymphoma worldwide, derives from natural killer or mature T cells (NK/TCL) and often involves the skin primarily or secondarily [1]. PTCL has a relatively higher morbidity rate in Asia and Central/South America, especially in populations infected with human T-cell lymphoma/leukemia virus-1 or Epstein-Barr virus (EBV) [2]. Diagnosis in PTCL has improved with the development of molecular, immunologic, and genetic techniques. However, there is still no consensus about standardized therapy in PTCL, although CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisone) or CHOP-like chemotherapy have been thought as the major regimen [3]. Progress in treatment of PTCL is much slow mainly due to disease rarity, biological heterogeneity, geographic variation, and limited recognition of the disease. To date, the prognosis of most PTCL types is extremely poor with a 5-year survival of 15–30% in the majority of series [1]. In recent years, bortezomib as a novel proteasome inhibitor, has shown good tolerance and therapeutic effect in PTCL besides defined indications for multiple myeloma and mantle cell lymphoma, which is bringing new light to PTCL patients [4, 5].

Here, we present a case of peripheral NK/TCL of the skin with positive EBV infection, in which bortezomib plus CHOP chemotherapy were used and led to rapid improvement and then complete remission (CR) for 11 months until local relapse. We also discussed the diagnosis, prognosis, and bortezomib- or plus CHOP-based treatment of PTCL according to this case and previously published data.

2. Case Report

In October 2007, a 66-year-old woman firstly visited a dermatology clinic with chief complaints of erythematous noduloplaques with mild tenderness and pitting edema on the right anterior tibial skin. She was diagnosed with dermatitis and continuously improved under infrared irradiation until April 2008, when similar dermatic lesions occurred on the left anterior tibial skin. She was diagnosed with dermatitis and continuously improved under infrared irradiation until April 2008, when similar dermatic lesions occurred on the left anterior tibial skin. In September 2008, the reddish-violet noduloplaques on both legs increased to a size of an hen’s egg, and the lesion on right leg even ulcerated and...
bled. The woman was then admitted to our hospital without a history of fever or weight loss. Physical examination showed multiple painless swollen lymph nodes of moderate hardness and limited motion in bilateral inguinal areas, which were assessed by color Doppler ultrasound with the largest one being 19 × 6 micrometer in size. A comprehensive metabolic profile displayed an elevated serum level of lactate dehydrogenase (LDH) of 256 U/L (normal: 60 to 240 U/l). Computerized tomography scan of the chest and abdomen was normal except for hepatic cysts.

The surgical resection and dermatoplasty of right leg lesion and biopsy of homolateral inguinal lymph nodes were carried out by plastic surgeons. Both the sections of invaded skin and lymph nodes histologically indicated peripheral NK/TCL of the nasal type with strongly positive CD56, CD43, CD3 and Ki67, but negative CD20, CD30, Bcl-2, and perforin by immunohistochemistry (Figures 1 and 2). EBV-encoded RNA (EBER) was positive in skin specimen by in situ hybridization. Serum anti-EBV capsid antigen (CA) IgM and antiearly antigen IgG were negative, but antinuclear antigen-1 IgG, anti-CA IgG, and anti-CA IgA were significantly positive.

The patient underwent a combination chemotherapy consisting of classical CHOP-21 plus bortezomib (1.3 mg/m²), which were administered by bolus injection on days 1, 4, 8, and 11, every 21 days. Simultaneously, acyclovir was intravenously used to protect against mucocutaneous infection with herpes simplex virus. The disease was quickly and significantly improved, which mainly displayed the diminishment noduloplaques, shrinking erythemas and swollen lymph nodes, decreasing edema, elimination of tenderness, and normalization of local skin temperature. She reached CR with mild brown pigmentation just after two courses of chemotherapy and received another two courses as consolidation (Figure 3). The therapy was well tolerated with only grade-two toxicities of neutropenia and thrombocytopenia. The patient remained in remission for 11 months but relapsed locally and became lost to followup at last.

3. Discussion

As for most PTCL patients with skin involvement but no B symptoms, cutaneous lesions are always significant enough to be initially identified and treated as common dermatitis at a dermatology clinic such as in this case. Detailed physical examination, especially lymph node examination, and prompt tissue biopsy are judicious choices prior to any medical management in order to avoid misdiagnosis and delay of correct treatment. Histologically, PTCL contains multiple subtypes including PTCL unspecified (PTCL-U), cutaneous TCL (CTCL), angioimmunoblastic TCL (AITL), anaplastic large-cell lymphoma (ALCL) noncutaneous, and hepatosplenic TCL (HSTCL) [2]. Adequate immunophenotyping is essential to exclude B-cell lymphomas and establish the specific type of PTCL by immunohistochemistry or flow cytometry. In our case, the immunostaining results of strongly positive CD3, CD43, CD56, and Ki67, but negative CD20, CD30, and Bcl-2, definitely supported the diagnosis of peripheral NK/TCL of the nasal type, although the negativity for perforin is indeed unusual [6].

Up to now, there is no standard efficient therapy for PTCL [1]. CHOP-like treatment, as the most commonly used first-line regimen for PTCL patients, is largely ineffective with low CR and high relapse rate except in anaplastic-lymphoma-kinase- (ALK)-positive ALCL [3, 7]. Some emerging evidence demonstrated that CHOP might not be appropriate as a chemotherapy backbone for PTCL patients since anthracyclines perhaps cannot influence the outcome, at least of PTCL-U [1, 8–10]. Previous data also suggested that expression of P-glycoprotein in PTCL possibly results in multidrug resistance to conventional systemic therapy, at least partly [11]. Other regimens that are more intensive than CHOP did not show any significant improvement in the overall survival of PTCL patients yet, with the exception of ALCL [12].

Bortezomib exerts an antitumor activity mainly through affecting the ubiquitin-proteasome pathway subsequently leading to inhibition of NF-κB and stabilization of proapoptotic proteins such as P53, Bcl-2, Bim, Bik, and Noxa [13]. It has been reported that NF-κB plays a critical role in the pathogenesis of CTCL, and that bortezomib can significantly cause NF-κB down-regulation and CTCL cell apoptosis [14]. Therefore, bortezomib may play a special therapeutic role and, at the same time, be safe from the emergence of acute toxicity in some types of PTCL due to its basic function mechanisms. As reported, an advanced HSTCL patient of gamma/delta type remained almost in CR for 27 months after 4 cycles of bortezomib plus the modified high-dose CHOP prior to autologous peripheral blood stem cell transplantation [15]. A phase clinical trial has confirmed that bortezomib indeed is safe and has significant single-agent activity in inducing remission (67% overall response rate, ORR), even CR (17%), in patients with relapsed or refractory CTCLs including mycosis fungoides and PTCL-U with isolated skin involvement [4]. The mentioned study also indicated that bortezomib leads to higher or at least comparable ORR compared with published data on gemcitabine, pegylated liposomal doxorubicin, 2-chlorodeoxyadenosine,
Figure 2: Sections of invaded skin and lymph nodes displaying strongly positive CD3 (cytoplasmic) (a), CD56 (b), CD43 (c), and Ki67 (d), but negative CD20 (e), CD30 (f), Bcl-2 (g), and perforin (h) by immunohistochemistry (×400).

Figure 3: Rapid remission in left leg lesions by bortezomib plus CHOP chemotherapy. (a) Day 0 in the first course. (b) Day 5 in the first course. (c) Day 8 in the first course. (d) Day 5 after the first course. (e) Day 7 after the second course. (f) Day 7 after the fourth course.

or pentostatin. Another recent phase I study demonstrated that PTCL patients consisting of PTCL-U, NK/TCL, ALC1, and angioimmunoblastic lymphoproliferative disease gained profits from the bortezomib plus CHOP therapy, with 61.5% ORR and unconfirmed CR rates [5]. The combined regimen just caused grade-4 neutropenia associated with febrile episode in one patient and grade-one peripheral sensory neuropathy in three patients, which indicated a good tolerance.

It has been reported that PTCL-U presenting in the skin has an unfavorable prognosis [16]. The outcome of PTCL appears to be associated with the International Prognostic Index (IPI), Prognostic Index for PTCL-U (PIT), and the International peripheral T-cell lymphoma Project score (IPTCLP), which are used for risk classification and response and survival prediction [3, 12, 17, 18]. In addition, EBV is positive in about 40% of PTCL, and some case series have reported that EBER-positive tumors have a worse outcome [3, 19]. Our patient belongs to the subgroup of high risk with bad prognosis because of poor prognostic indexes due to multiple risk factors: >60 years of age, ECOG performance status >2, late stage, elevated serum LDH, number of extranodal sites of involvement >1, high Ki67 expression, and positive EBV infection [20, 21]. Anyway,
the adopted regimen showed enough safety and quickly led to satisfied therapeutic effects in this case. Therefore, the bortezomib plus CHOP chemotherapy is safe and efficient in peripheral NK/TCL according to our case and the literature review, although further large-sized clinical trials with long-period followup are still needed.

Conflict of Interests

The authors did not receive any grants or financial support and have no financial interest in the products presented in this work.

References

[1] K. J. Savage, “Peripheral T-cell lymphomas,” Blood Reviews, vol. 21, no. 4, pp. 201–216, 2007.
[2] L. de Leval and P. Gaulard, “Pathobiology and molecular profiling of peripheral T-cell lymphomas,” Hematology/the Education Program of the American Society of Hematology, pp. 272–279, 2008.
[3] Y. Lee, J. E. Uhm, H. Y. Lee et al., “Clinical features and prognostic factors of patients with "peripheral T-cell lymphoma, unspecified," Annals of Hematology, vol. 88, no. 2, pp. 111–119, 2009.
[4] P. L. Zinzani, G. Musuraca, M. Toni et al., “Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 27, pp. 4293–4297, 2007.
[5] J. Lee, C. Suh, H. J. Kang et al., “Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma,” Annals of Oncology, vol. 19, no. 12, pp. 2079–2083, 2008.
[6] S. H. Swerdlow, E. Campo, N. L. Harris et al., Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, World Health Organization Classification of Tumours, chapter 11.270–299367, International Agency for Research on Cancer Press, Lyon, France, 2008.
[7] M. T. Fierro, G. C. Doveil, P. Quaglino, P. Savoia, A. Verrone, and M. G. Bernengo, “Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma,” Dermatology, vol. 194, no. 3, pp. 268–272, 1997.
[8] J. Vose, “The international PTCL project internal medicine, University of Nebraska Medical Center, Omaha, NE, USA, "International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines," Session type: Oral Session,” Blood, vol. 106, p. 811a, 2005.
[9] J. M. Vose, M. Neumann, and M. E. Harris, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008.
[10] P. P. Piccaluga, C. Agostinelli, A. Califano et al., “Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 823–834, 2007.
[11] J. Y. You, K. H. Chi, M. H. Yang et al., “Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan,” Annals of Oncology, vol. 15, no. 4, pp. 618–625, 2004.
[12] K. J. Savage, “Prognosis and primary therapy in peripheral T-cell lymphomas,” Hematology/the Education Program of the American Society of Hematology, pp. 280–288, 2008.
[13] D. J. McConkey and K. Zhu, “Mechanisms of proteasome inhibitor action and resistance in cancer,” Drug Resistance Updates, vol. 11, no. 4–5, pp. 164–179, 2008.
[14] A. Sors, F. Jean-Louis, C. Pellet et al., “Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis,” Blood, vol. 107, no. 6, pp. 2354–2363, 2006.
[15] Z. K. Otrock, H. A. Hatoun, Z. M. Salem et al., “Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation,” Annals of Hematology, vol. 87, no. 12, pp. 1023–1024, 2008.
[16] M. W. Bekkenk, M. H. Vermeer, P. M. Jansen et al., “Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients,” Blood, vol. 102, no. 6, pp. 2213–2219, 2003.
[17] A. Gallamini, C. Stelitano, R. Calvi et al., “Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study,” Blood, vol. 103, no. 7, pp. 2474–2479, 2004.
[18] G. Gutiérrez-Garcia, A. Garcia-Herrera, T. Cardesa et al., “Comparison of four prognostic scores in peripheral T-cell lymphoma,” Annals of Oncology. In press.
[19] J. Dupuis, J. F. Emile, N. Mounier et al., “Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study,” Blood, vol. 108, no. 13, pp. 4163–4169, 2006.
[20] J. Lee, C. Suh, H. P. Yeon et al., “Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 612–618, 2006.
[21] J. Suzumiya, K. Ohshima, K. Tamura et al., “The International Prognostic Index predicts outcome in aggressive adult T-cell lymphoma/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project,” Annals of Oncology, vol. 20, no. 4, pp. 715–721, 2009.